Ono Pharmaceutical Company Profile

Aggregated data from the web about Ono Pharmaceutical

Company Name	Ono Pharmaceutical
Website	https://www.ono.co.jp
Snippet	ONO Receives Approval of Opdivo® (Nivolumab) for Additional Indications of Unresectable Advanced or Recurrent Esophageal Cancer, and MSI-High Unresectable Advanced or Recurrent Colorectal Cancer in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval. BMSKK and ONO Receive Approval of Orencia® for I.V. Infusion,
ISIN	JP3197600004
Type	Public (K.K)
Founded	1717
Founder	Ichibei Ono I
Revenue	JPY 261.8 billion (FY 2017) (US$ 2.4 billion) (FY 2017)
Website	Official website
Industry	Pharmaceuticals
Products	Pharmaceuticals, Diagnostic reagents
Traded as	TYO: 4528
Key people	Gyo Sagara(President and CEO)
Net income	JPY 50.2 billion (FY 2017) (US$ 474 million) (FY 2017)
Area served	Worldwide
Native name	小野薬品工業
Headquarters	Chuo-ku, Osaka, 541-8564, Japan
Number of employees	3,576 (consolidated, as of September 30,2018)

Ono Pharmaceutical is part of the Japan company list

Ono Pharmaceutical is part of the Pharmaceuticals company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.